Biodesix to Participate in Upcoming Investor Conferences
Biodesix (BDSX) will participate in three investor conferences in September 2026, focusing on meetings with investors and a scientific panel appearance in New York.
Rhea-AI Summary
Biodesix (BDSX) will participate in three investor conferences in September 2026, focusing on meetings with investors and a scientific panel appearance in New York.
The company will attend Lake Street Capital Markets’ 10th Annual Best Ideas Growth (BIG10) Conference for 1x1 meetings on Thursday, September 10, and the H.C. Wainwright 28th Annual Global Investment Conference for 1x1 meetings on Tuesday, September 15, both in New York. Biodesix will also join the 5th Annual Roth Healthcare Opportunities Conference in New York, where Chief Scientific Officer Gary Pestano, Ph.D., will speak on a panel titled “The Rise of MRD Monitoring in Solid Tumors, and Where it Goes Next” on Tuesday, September 29 at 2:00 PM ET.
Positive
- None.
Negative
- None.
AI-generated analysis. How Rhea-AI works. Not financial advice.
LOUISVILLE, Colo., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions company, today announced that members of the Biodesix leadership team will present in three upcoming investor conferences:
Lake Street Capital Markets’ 10th Annual Best Ideas Growth (BIG10) Conference
1x1 meetings only
Date: Thursday, September 10
Location: New York, NY
H.C. Wainwright 28th Annual Global Investment Conference
1x1 meetings only
Date: Tuesday, September 15
Location: New York
5th Annual Roth Healthcare Opportunities Conference
Panel and 1x1 meetings
Panel Title: The Rise of MRD Monitoring in Solid Tumors, and Where it Goes Next
Biodesix Presenter: Gary Pestano, Ph.D., Chief Scientific Officer
Panel Date and Time: Tuesday, September 29, 2:00 PM ET
Location: New York
About Biodesix:
Biodesix is a leading diagnostic solutions company, driven to improve clinical care and outcomes for patients. Biodesix Diagnostic Tests, including Nodify Lung® Nodule Risk Assessment and IQLung® Cancer Treatment Guidance, support clinical decisions to expedite personalized care and improve outcomes for patients with lung disease. Biodesix Development Services enable the world’s leading biopharmaceutical, life sciences, and research institutions with scientific, technological, and operational capabilities that fuel the development of diagnostic tests, tools, and therapeutics. For more information, visit biodesix.com.
Biodesix Contacts:
Media:
Natalie St. Denis, Director Corporate Communications
natalie.stdenis@biodesix.com
(720) 925-9285
Investors:
Chris Brinzey, Partner, ICR
chris.brinzey@icrhealthcare.com
(339) 970-2843
FAQ
Which investor conferences will Biodesix (BDSX) attend in September 2026?
Biodesix will attend three events in New York: Lake Street Capital Markets’ 10th Annual Best Ideas Growth (BIG10) Conference on September 10, the H.C. Wainwright 28th Annual Global Investment Conference on September 15, and the 5th Annual Roth Healthcare Opportunities Conference on September 29.
What is Biodesix (BDSX) doing at the Lake Street BIG10 and H.C. Wainwright conferences?
At both the Lake Street Capital Markets BIG10 Conference on September 10 and the H.C. Wainwright 28th Annual Global Investment Conference on September 15, Biodesix leadership will participate in 1x1 investor meetings only, with no public presentation announced.
What panel will Biodesix join at the Roth Healthcare Opportunities Conference for BDSX?
At the 5th Annual Roth Healthcare Opportunities Conference, Biodesix Chief Scientific Officer Gary Pestano, Ph.D., will speak on a panel titled “The Rise of MRD Monitoring in Solid Tumors, and Where it Goes Next” on Tuesday, September 29 at 2:00 PM ET in New York.